Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

This study is testing whether cemiplimab — an immunotherapy drug that helps the immune system fight cancer — can maintain disease control in patients with advanced adrenal cortex cancer (adrenocortical carcinoma) who responded to an initial round of chemotherapy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with adrenocortical carcinoma (cancer of the outer part of the adrenal gland) confirmed by biopsy - You completed 4 to 6 rounds of a standard chemotherapy regimen (EDP-M) without disease progression - You had surgery to remove as much tumor as possible if appropriate - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your cancer progressed during or after initial chemotherapy - You have active autoimmune disease requiring treatment - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.